HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.
June 28, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics (NASDAQ:RGLS) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $9.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $9 indicates the firm's confidence in the stock's potential to reach this price, which could lead to an increase in investor interest and potentially a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100